David M Gardner
Overview
Explore the profile of David M Gardner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
1197
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Murphy A, Sawires K, Peltekian S, Helwig M, Macdonald M, Martin-Misener R, et al.
Explor Res Clin Soc Pharm
. 2024 Dec;
16:100538.
PMID: 39634377
Background: Benzodiazepines and -drugs (e.g., zopiclone, zolpidem) (benzodiazepine receptor agonists or BZRAs), are prescribed for anxiety and insomnia disorders. However, they are not indicated as first line therapies for long-term...
2.
Gardner D, Turner J, Magalhaes S, Rajda M, Murphy A
JAMA Psychiatry
. 2024 Sep;
81(12):1187-1197.
PMID: 39292452
Importance: Direct-to-patient interventions enabling transitions from long-term benzodiazepine receptor agonist (BZRA) use to cognitive behavioral therapy for insomnia (CBTI) by older adults has the potential to reduce BZRA use and...
3.
Katmeh T, Gardner D, Kiepek N, Macdonald M, Murphy A
J Sleep Res
. 2024 Jun;
34(1):e14282.
PMID: 38945830
Benzodiazepine receptor agonists are often used for insomnia in older adults contrary to current evidence. The harms outweigh the benefits, which are limited. Cognitive behavioural therapy for insomnia is the...
4.
Murphy A, Turner J, Rajda M, Allen K, Gardner D
Can J Aging
. 2024 Mar;
43(4):529-537.
PMID: 38456246
Behavioural treatments are recommended first-line for insomnia, but long-term benzodiazepine receptor agonist (BZRA) use remains common and engaging patients in a deprescribing consultation is challenging. Few deprescribing interventions directly target...
5.
McAdam M, Baldessarini R, Murphy A, Gardner D
J Psychopharmacol
. 2023 Oct;
37(10):982-991.
PMID: 37842908
Background: Expert consensus-based clinically equivalent dose estimates and dosing recommendations can provide valuable support for the use of drugs for psychosis in clinical practice and research. Aims: This second International...
6.
Murphy A, Suh S, Gillis L, Morrison J, Gardner D
Pharmacy (Basel)
. 2023 Mar;
11(2).
PMID: 36961024
Long-acting injectable antipsychotics (LAIAs) have demonstrated positive outcomes for people with serious mental illnesses. They are underused, and access to LAIAs can be challenging. Pharmacies could serve as suitable environments...
7.
8.
Murphy A, Turner J, Rajda M, Allen K, Pinter K, Gardner D
Explor Res Clin Soc Pharm
. 2022 Dec;
9:100214.
PMID: 36540425
Background: Recruitment to clinical trials is a challenge for researchers that became more pronounced because of COVID-19 public health protective measures, especially with respect to studies enrolling older adults. We...
9.
Murphy A, Turner J, Rajda M, Magalhaes S, Allen K, Gardner D
Explor Res Clin Soc Pharm
. 2022 Sep;
7:100164.
PMID: 36045710
Background: Chronic benzodiazepine receptor agonist (BZRA) use among older adults is a public health concern given cognitive and physical risks. One in four older adults in New Brunswick, Canada, is...
10.
Murphy A, Simon K, Pelletier E, Miller L, Gardner D
Can Pharm J (Ott)
. 2022 Mar;
155(2):93-100.
PMID: 35300027
No abstract available.